FDA Grants Accelerated Approval to Nivolumab for Small Cell Lung Cancer

The decision was based on the ongoing CheckMate-032 phase 1/2 study, in which researchers are investigating nivolumab in patients with advanced or metastatic tumors.

from Latest articles from Cancer Therapy Advisor Lung Cancer https://ift.tt/2MT3QIl